Document Detail

Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration.
MedLine Citation:
PMID:  2189957     Owner:  NLM     Status:  MEDLINE    
This clinical trial was performed to study the effects of intravenously (IV) administered recombinant human (rh) erythropoietin (EPO) at escalating doses (150, 300, and 450 U/kg, administered as an IV bolus injection, twice weekly, for 6, 4, and 4 weeks, respectively) in five patients with low-grade non-Hodgkin's lymphoma (Ig NHL) and bone marrow involvement and one patient with multiple myeloma (MM). All patients were anemic due to underlying disease. None of the patients had a history of bleeding, hemolysis, renal insufficiency, or other disorders causing anemia in addition to bone marrow infiltrating malignancy. Endogenous EPO serum levels were significantly increased in all patients (74 to 202 mU/mL). Five patients (one MM, four small-cell lymphocytic [SCLC] NHL) showed a dramatic increase of hemoglobin (Hb), hematocrit (Hk) and RBC count becoming obvious on the second EPO dose level. Initial ferritin serum values, which were high mostly due to polytransfusion, were significantly reduced in responding patients. Erythropoiesis of one patient with extensive follicular mixed (fm) NHL did not respond to EPO treatment. Platelet (PLT) count increase (greater than 75% above starting levels) during and following EPO therapy was observed in one patient with MM. Adverse events due to EPO therapy have not been recorded. These findings point out a previously unrecognized capacity of EPO given at pharmacologic doses to stimulate erythropoiesis in patients with anemia due to bone marrow infiltration by neoplastic lymphocytes in spite of enhanced endogenous EPO expression.
W Oster; F Herrmann; H Gamm; G Zeile; A Lindemann; G Müller; T Brune; H P Kraemer; R Mertelsmann
Related Documents :
16424657 - Trisomy 8 in prefibrotic early stages of chronic idiopathic myelofibrosis: a fluorescen...
18575157 - Effect of atorvastatin on bone mineral density in patients with acute coronary syndrome.
21136017 - γ'/total fibrinogen ratio is associated with short-term outcome in ischaemic stroke.
9676757 - Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in...
20806087 - Colposcopic evaluation of cervix with persistent inflammatory pap smear: a prospective ...
22180357 - Lymphocyte-suppressing action of angiotensin-converting enzyme inhibitors in coronary a...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  8     ISSN:  0732-183X     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  1990 Jun 
Date Detail:
Created Date:  1990-07-06     Completed Date:  1990-07-06     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  956-62     Citation Subset:  IM    
Department of Hematology, Johannes Gutenberg-University, Mainz, Federal Republic of Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia / drug therapy*,  etiology
Blood Coagulation / physiology
Bone Marrow / pathology*
Clinical Trials as Topic
Erythropoiesis / drug effects
Erythropoietin / adverse effects,  blood,  therapeutic use*
Ferritins / blood
Hematopoiesis / drug effects
Middle Aged
Neoplasms / complications,  drug therapy,  pathology
Tumor Necrosis Factor-alpha / analysis
Reg. No./Substance:
0/Tumor Necrosis Factor-alpha; 11096-26-7/Erythropoietin; 9007-73-2/Ferritins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic ur...
Next Document:  Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high...